VYNE Therapeutics (VYNE) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VYNE shares.
View VYNE analyst ratings or view top-rated stocks.

2 analysts have issued 12-month price targets for VYNE Therapeutics' stock. Their VYNE share price forecasts range from $9.00 to $28.00. On average, they expect the company's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 228.6% from the stock's current price.
View analysts price targets for VYNE or view top-rated stocks among Wall Street analysts.

VYNE Therapeutics' stock was trading at $2.70 at the beginning of 2023. Since then, VYNE shares have increased by 108.5% and is now trading at $5.63.
View the best growth stocks for 2023 here.

VYNE Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 91,900 shares, a decrease of 55.6% from the April 30th total of 206,800 shares. Based on an average daily volume of 702,800 shares, the short-interest ratio is presently 0.1 days. Approximately 2.9% of the company's shares are short sold.
View VYNE Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our VYNE earnings forecast.

VYNE Therapeutics Inc. (NASDAQ:VYNE) posted its earnings results on Thursday, May, 11th. The company reported ($1.74) earnings per share for the quarter, topping analysts' consensus estimates of ($2.50) by $0.76. The company earned $0.10 million during the quarter. VYNE Therapeutics had a negative net margin of 8,417.59% and a negative trailing twelve-month return on equity of 84.52%.

Shares of VYNE Therapeutics reverse split on the morning of Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Organigram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS).

VYNE Therapeutics trades on the NASDAQ under the ticker symbol "VYNE."

VYNE Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include DSC Advisors L.P. (3.52%), BlackRock Inc. (1.50%), Renaissance Technologies LLC (0.78%), Geode Capital Management LLC (0.76%), Staley Capital Advisers Inc. (0.72%) and Susquehanna International Group LLP (0.55%). Insiders that own company stock include Andrew Saik, David Domzalski, Mutya Harsch, Patrick G Lepore and Perceptive Advisors Llc.
View institutional ownership trends.

Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VYNE stock can currently be purchased for approximately $5.63.

VYNE Therapeutics (NASDAQ:VYNE) has a market capitalization of $18.41 million and generates $480,000.00 in revenue each year. The company earns $-23,210,000.00 in net income (profit) each year or ($10.6455) on an earnings per share basis.

VYNE Therapeutics' mailing address is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. The official website for the company is vynetherapeutics.com. The company can be reached via phone at (800) 755-7936 or via email at jallaire@lifesciadvisors.com.